Valeria de Mello-Coelho

Dr. Valeria de Mello-Coelho

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MSMarilia Kimie Shimabukuro
Marilia Kimie Shimabukuro
LLLarissa Gutman Paranhos Langhi
Larissa Gutman Paranhos Langhi
ICIngrid Rosenburg Cordeiro
Ingrid Rosenburg Cordeiro
JBJosé M. Brito
José M. Brito
CBClaudia Maria de Castro Batista
Claudia Maria de Castro Batista
VMValeria de Mello-Coelho
Valeria de Mello-Coelho
We characterized cerebral Oil Red O-positive lipid-laden cells (LLC) of aging mice evaluating their distribution, morphology, density, functional activities and inflammatory phenotype. We identified LLC in meningeal, cortical and neurogenic brain regions. The density of cerebral LLC increased with age. LLC presenting small lipid droplets were visualized adjacent to blood vessels or deeper in the brain cortical and striatal parenchyma of aging mice. LLC with larger droplets were asymmetrically distributed in the cerebral ventricle walls, mainly located in the lateral wall. We also found that LLC in the subventricular region co-expressed beclin-1 or LC3, markers for autophagosome or autophagolysosome formation and perilipin (PLIN), a lipid droplet-associated protein, suggesting lipophagic activity. Some cerebral LLC exhibited β galactosidase activity indicating a senescence phenotype. Moreover, we detected production of the pro-inflammatory cytokine TNF-α in cortical PLIN+ LLC. Some cortical NeuN+ neurons, GFAP+ glia limitans astrocytes, Iba-1+ microglia and S100β+ ependymal cells expressed PLIN in the aging brain. Our findings suggest that cerebral LLC exhibit distinct cellular phenotypes and may participate in the age-associated neuroinflammatory processes.

27 October 2004 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
LRLeticia B.A. Rangel
Leticia B.A. Rangel
RARachana Agarwal
Rachana Agarwal
CSCheryl A. Sherman-Baust
Cheryl A. Sherman-Baust
VMValeria de Mello-Coelho
Valeria de Mello-Coelho
EPEllen S. Pizer
Ellen S. Pizer
PMPatrice J. Morin
Patrice J. Morin
Tumor formation in immunocompetent hosts is believed to be dependent on the ability of tumor cells to evade the immune system, as suggested by the alterations of expression of the major histocompat...

1 July 2005 in Endocrinology
Verified
Journal Article
Closed access
SSSalete Smaniotto
Salete Smaniotto
VMValeria de Mello-Coelho
Valeria de Mello-Coelho
DVDéa Maria Serra Villa-Verde
Déa Maria Serra Villa-Verde
JPJean-Marie PléaU
Jean-Marie PléaU
MPMarie-Catherine Postel-Vinay
Marie-Catherine Postel-Vinay
WSWilson Savino
Wilson Savino
Previous evidence indicates that GH modulates thymic cell migration. In this study we approached this issue in vivo, studying thymocyte migration in GH transgenic animals and in normal mice treated intrathymically with GH. Extracellular matrix and chemokines are involved in thymocyte migration. In this respect, thymocyte adhesion to laminin was higher in GH-treated animals than controls, and the numbers of migrating cells in laminin-coated Transwells was higher in GH-transgenic and GH-injected mice. Additionally, CXC chemokine ligand 12 (CXCL12)-driven migration was higher in GH-Tg and GH-treated animals compared with controls. Interestingly, although CXCR4 expression on thymocytes did not change in GH-Tg mice, the CXCL12 intrathymic contents were higher. We found that CXCL12, in conjunction with laminin, would additionally enhance the migration of thymocytes previously exposed to high concentrations of GH in vivo. Lastly, there was an augmentation of recent thymic emigrants in lymph nodes from GH-Tg and GH-injected animals. In conclusion, enhanced thymocyte migration in GH transgenic mice as well as GH-injected mice results at least partially from a combined action of laminin and CXCL12. Considering that GH is presently being used as an adjuvant therapeutic agent in immunodeficiencies, including AIDS, the concepts defined herein provide important background knowledge for future GH-based immune interventions.

27 June 2009 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
LBLeandra Santos Baptista
Leandra Santos Baptista
KSKarina Ribeiro da Silva
Karina Ribeiro da Silva
CPCarolina Silva Gouveia da Pedrosa
Carolina Silva Gouveia da Pedrosa
CCCesar Claudio-Da-Silva
Cesar Claudio-Da-Silva
JCJoão Regis Ivar Carneiro
João Regis Ivar Carneiro
RBRadovan Borojevic
Radovan Borojevic

1 February 2002 in Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
VMValeria de Mello-Coelho
Valeria de Mello-Coelho
DVDéa Maria Serra Villa-Verde
Déa Maria Serra Villa-Verde
DFDésio Aurélio Farias-De-Oliveira
Désio Aurélio Farias-De-Oliveira
JBJosé Marques de Brito
José Marques de Brito
MDMireille Dardenne
Mireille Dardenne
WSWilson Savino
Wilson Savino
Interactions between thymocytes and thymic epithelial cell (TEC) can be modulated by growth hormone via insulin-like growth factor-1 (IGF-1). In this study, we showed IGF-1 and IGF-1 receptor mRNA expression by human and murine TEC and thymocytes. Functionally, IGF-1 stimulates extracellular matrix production by human TEC. Moreover, pretreatment of murine TEC with IGF-1 increases their adhesion to thymocytes. Interestingly, we observed an increase in the frequency of CD4–CD8–CD90+ T cells which adhered to pretreated TEC, supporting the concept that IGF-1 may also act indirectly on intrathymic T cell differentiation and migration through the thymic epithelium.

1 September 1998 in Endocrinology
Verified
Journal Article
Closed access
VMValeria de Mello-Coelho
Valeria de Mello-Coelho